The Orange Book's Blind Spot: Process Stability And Capability

By Ajaz S. Hussain, Ph.D., independent practitioner of pharmaceutical science

For 46 editions, the Orange Book has answered one question with admirable economy: can this product be substituted for that one? Its two-letter therapeutic equivalence (TE) codes — AA, AB, and their less fortunate B-rated cousins — are read daily by pharmacists, formulary committees, state substitution programs, and procurement officers who rarely look past the first letter. Now published monthly and exposed through an open data API, the Orange Book is more accessible than ever.¹ Its signaling function, however, has not evolved with the manufacturing reality it is meant to represent.

The Orange Book was built for a domestic industry in which cGMP compliance could reasonably be presumed. That industry has not existed for decades. The globalized supply chain exhibits wide variability in oversight, inspection parity, and process robustness — variability the current TE framework cannot express. Therapeutic equivalence demonstrated at approval is, in practice, an expectation about future performance; continued process verification is how that expectation is justified across the product’s commercial life.² Making the justification visible — through process stability and capability signals such as AB-CPK for conventional manufacturing and AB-AMT-CPK for designated advanced manufacturing platforms — would close a longstanding blind spot. It would allow TE codes to reflect not only equivalence at approval but the demonstrated capability of the process that sustains equivalence in real-world use.

This column extends an argument developed in earlier work: that the system for assuring therapeutic equivalence contains structural blind spots,³ that uneven global cGMP oversight magnifies them,⁴ and that institutions must evolve toward resilience rather than merely adding corrective actions.⁵ The Orange Book is where those threads converge, because it is the one regulatory instrument that translates that complexity into a public signal.

The Orange Book was first published in 1980 to facilitate cost-saving generic substitution, not to serve as an ongoing quality dashboard. A point-in-time snapshot of evidence at the moment of approval was then deemed sufficient.

By FDA’s own definition, therapeutic equivalents are approved drug products that are pharmaceutical equivalents, are bioequivalent, are adequately labeled, and are manufactured in compliance with cGMP regulations.⁶ The definition is sound. The problem lies in how its four elements are evidenced. Pharmaceutical equivalence and bioequivalence are demonstrated affirmatively, with data, at the time of approval. cGMP compliance, by contrast, is observational and often a presumed status that persists until the next adversarial inspection, a recall, or a shortage says otherwise.

An A rating reflects a point‑in‑time judgment. It is an approval‑stage designation, not a real‑time performance indicator. It offers no assurance that the process used to produce the typically single bio‑batch is truly representative of commercial manufacturing unless the commercial process is operating under the same state of control that governed the bio lot.

And critically, the code provides no visibility into that distinction. A reader cannot tell whether an AB product comes from a continuously verified, statistically capable line or from a site struggling with recurring out‑of‑specification investigations and a pending warning letter. On the page, both products look identical.

A holistic systems approach must weigh all four elements across the product’s commercial life, not only at approval. The Orange Book, as currently structured, cannot express that wholeness. It compresses a life cycle into a snapshot.

The irony is that FDA has, since January 2011, defined the evidentiary framework that would close this gap. The process validation guidance replaced the “three conforming batches” mindset with a life cycle: Stage 1 process design, Stage 2 process qualification, and Stage 3 continued process verification, in which manufacturers collect and statistically trend data sufficient to detect drift and confirm that the process remains in a state of control.²

Without ongoing assurance of process stability and capability consistent with those 2011 principles, therapeutic equivalence demonstrated at approval cannot be assumed to persist in real-world use. Content uniformity, dissolution, assay, impurity profiles, and sterility assurance are not static properties of a product. They are outputs of a process whose variability is governed by raw material lots, equipment condition, operator practice, and site culture. A product whose critical quality attributes run with a process capability index comfortably above the commonly cited threshold of 1.33 is, in a meaningful physical sense, a different risk to patients than one hovering near 1.0 and relying on release testing to catch excursions. Nothing in the current TE framework distinguishes them.

Annual product reviews and annual reports should ideally include process capability metrics, and the underlying data are already generated as part of Stage 3 and CPV activities. Many firms routinely track these metrics in annual product reviews, continued process verification reports, and quality metrics programs. What is missing is not measurement but signal — a publicly visible, regulator-verified indicator that reduces the information asymmetry between manufacturers and the market without exposing proprietary raw data.

Even if FDA’s oversight (e.g., domestic vs. overseas) were equivalent, presumed cGMP compliance is still only a proxy for process capability. FDA itself has emphasized that the two are not interchangeable. When announcing the expansion of unannounced foreign inspections on May 6, 2025, the agency described a longstanding “double standard” in which foreign facilities received advance notice while domestic manufacturers did not.⁷

The U.S. Government Accountability Office has kept oversight of the global pharmaceutical supply chain on its High-Risk List since 2009 and has documented the practice of preannouncing foreign inspections, often by as much as 12 weeks.⁸ In fiscal year 2023, nearly 90 percent of FDA’s foreign inspections were preannounced — a figure reported from FDA correspondence with Congress and subsequently summarized in contemporary legal analysis.⁹ Inspection parity is necessary, not sufficient. Inspections sample compliance; they do not continuously measure capability. When two ANDA holders carry the same AB code, but one is inspected unannounced every two years and the other was last seen on a preannounced visit five years ago, the code is not merely uninformative. It masks a difference in assurance.

That difference has a population-level clinical residue. For instance, in a matched analysis of 2,443 generic drugs, Noh, Gray, Ball, and colleagues found that products manufactured in certain foreign facilities were associated with roughly 54 percent more serious adverse event reports than equivalent U.S.-made products. The excess burden was concentrated in mature generics, the segment under the greatest price pressure.¹⁰ Crucially, that study measured adverse outcomes, not process capability indices or the implementation of effective quality-by-design principles.

Mechanistic work on legacy narrow-therapeutic-index (NTI) products such as levothyroxine sodium pentahydrate — one of the most frequently prescribed drugs in the United States — reveals failure modes not accounted for in practice. Dehydration of the crystal hydrate at low humidity or under process stress opens lattice channels, admits oxygen, and initiates oxidative potency loss, all while the packing motif persists, to varying degrees, even after the hydrate is fully dehydrated and the lattice disorders — and therefore points to residual uncertainty that can remain unaccounted over decades.¹¹ The conclusion that legacy NTI therapeutic equivalence considerations require “new prior knowledge” and a holistic systems approach, not merely tighter bioequivalence limits, is a canary in the coal mine and illustrative of a broader blind spot.^12,13

Policymakers have begun to respond to the consequences of that asymmetry. The Senate Special Committee on Aging held hearings on foreign generic quality and supply chain risk in September and October 2025.^14,15 The Department of Defense launched independent quality scoring of military-essential generics in 2023.¹⁶ And ProPublica’s Rx Inspector (December 2025) and a May 2026 investigative podcast challenged the status quo by providing a glimpse into factory-level and inspection history information that the public Orange Book does not show.^17,18 These efforts all point to the same structural gap: when capability exists, the market cannot see it.

The Orange Book is already a living database. The Orange Book Transparency Act prompted public comment on modernization; FDA’s 2022 report to Congress on patent listing in the Orange Book found no consensus on modernization of that column.¹⁹ Process capability signaling offers a practical path to resolving the current impasse. It aligns with CDER’s Quality Management Maturity (QMM) program, which is already shifting the agency away from lagging indicators and toward predictive measures — including process capability, statistical control, and right‑first‑time performance. This evolution is reflected in FDA’s descriptions of QMM as a framework that encourages manufacturers to adopt advanced quality systems capable of early detection, continual improvement, and reliable performance.²⁰

Consider a suffix appended to the existing code for conventional manufacturing: AB-CPK. The suffix would not publish a raw Cpk value — which varies by attribute, is easily gamed by specification width, and would invite misinterpretation. Instead, it would indicate that the applicant has submitted, and FDA has verified, Stage 3 process capability evidence meeting a defined standard for the product’s critical quality attributes over a defined reporting period. Products lacking current verification would temporarily retain their AB rating but without the suffix until they provide, in the next annual report, satisfactory capability metrics. Absence of the suffix would not be a B rating and would not be a finding of inequivalence. What would change is the transparency of the assurance behind it.

That blind spot becomes more consequential as products migrate to advanced manufacturing technology (AMT) platforms. Section 506L of the Federal Food, Drug, and Cosmetic Act — established by the Food and Drug Omnibus Reform Act and implemented through FDA’s December 2024 final guidance — allows applicants to reference a designated AMT (continuous flow, automation, three-dimensional printing, process analytical technology-enabled real-time release, and similar approaches) in NDAs, ANDAs, and biologics license applications.^21,22 The first AMT designations were granted in 2025, and FDA’s PreCheck pilot, launched under Executive Order 14293, selected its initial cohort of seven new domestic facilities on June 29, 2026.^23,24 Some of these platforms can generate continued process verification as a byproduct of operation — precisely the kind of capability evidence missing not just for legacy NTIs but for all products.

A signal such as AB-AMT-CPK would recognize that distinction: therapeutically equivalent, manufactured on a designated AMT platform, and supported by continuously verified capability data. Resilience that is invisible at the point of purchase cannot be rewarded by the market. Without such a signal, federal buyers and group purchasing organizations have no regulator-verified way to prefer a capable domestic AMT product over an undifferentiated import, and the incentive collapses to price.

Congress is already moving toward greater manufacturing disclosure. The CLEAR LABELS Act (S. 3788), introduced February 5, 2026, and its House companion (H.R. 8269), introduced April 14, 2026, would require prescription drug labeling to identify the original manufacturer of each active pharmaceutical ingredient and of the finished product.^25,26 The Senate Committee on Health, Education, Labor, and Pensions advanced S. 3788 by a 21–1 vote on July 22, 2026.²⁷ These reforms may address where a product comes from — but they cannot address how well it is made; only FDA can.

As currently drafted, the legislation advances origin transparency, not quality transparency. A label that identifies the API manufacturer and the finished dose manufacturer still tells the reader nothing about the facility’s process capability, its state of control, its history of out‑of‑specification investigations, or whether it operates under a mature quality system. Origin disclosure answers where a drug is made. It does not answer how well it is made. That gap is precisely where FDA can lead — by pairing origin transparency with quality‑system signaling that reflects real manufacturing performance rather than static approval‑stage attributes.

Country of origin disclosure gives patients and clinicians basic supply chain visibility, but it does not provide FDA-verified evidence‑based assurance of quality. Without a market signal for quality, origin information cannot influence purchasing decisions, and advanced domestic AMT platforms are forced to compete in a market that defaults to price, not performance.

Quality uncertainty also affects adherence: when patients doubt the reliability of their medicines, they skip doses, delay refills, or abandon therapy, creating avoidable clinical and economic harm. Process capability signaling is the necessary complement to origin transparency. It shifts the focus from geography to manufacturing performance, and the Orange Book — already digital, trusted, and universally used — offers a ready vehicle for FDA to lead in implementing that shift.

FDA can implement a process‑capability signal under existing authority. The agency already updates TE codes when new information warrants, including when facility issues undermine the basis of an original evaluation.²⁸ Because cGMP compliance is already embedded in the criteria for an A rating, distinguishing how that compliance is demonstrated fits squarely within FDA’s current evaluative framework and does not alter the underlying TE codes or state substitution laws.

Industry is already required to maintain continued process verification, and AMT platforms make those expectations far easier to meet at scale. What is needed now is a coordinated educational effort and a concise Q&A‑style FDA guidance that clarifies how continued verification evidence should be organized, documented, and presented for submissions and inspections within a dynamic AB rating framework. This small regulatory clarification would unlock a consistent, predictable pathway for stability and capability‑based signaling.

For policymakers, the next step is to link the signal to procurement, ensuring federal purchasing and stockpiling reward regulator‑verified manufacturing capability rather than geography or self‑attestation. This pairing would allow origin transparency to evolve into performance transparency, strengthening both supply chain resilience and patient outcomes.

Therapeutic equivalence cannot remain a static badge earned on approval day. As the gap between presumed compliance and demonstrated capability widens, the risks to patients and the vulnerabilities in the supply chain have become impossible to ignore. Closing this blind spot requires a regulatory instrument that reflects real‑world manufacturing performance, not historical expectation.

The solution is clear: evolve the Orange Book into a dynamic digital publication capable of carrying AB‑CPK and AB‑AMT‑CPK signals. Give modern manufacturing a modern signal. Give domestic advanced platforms the visibility their economics depend on. Align FDA’s most‑read public database with the transparency Congress and patients already expect.

About The Author:

Ajaz S. Hussain, Ph.D., is a pharmaceutical quality and regulatory science expert with decades of experience across academia, industry, and government. As a former deputy director of the FDA's Office of Pharmaceutical Science, he was pivotal in pioneering initiatives like the process analytical technology (PAT) framework and the Pharmaceutical Quality for the 21st Century Initiative. Hussain also served as president of the National Institute for Pharmaceutical Technology and Education (NIPTE), advancing pharmaceutical technology and regulatory science. Now an independent consultant, he empowers organizations to integrate design thinking with a systems approach to advance innovative technologies that hold high potential for enhancing patient care and operational excellence.